Paul Tudor Jones Rocket Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 31,125 shares of RCKT stock, worth $183,948. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,125
Previous 16,787
85.41%
Holding current value
$183,948
Previous $310,000
26.13%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RCKT
# of Institutions
244Shares Held
94.6MCall Options Held
262KPut Options Held
159K-
Rtw Investments, LP New York, NY17.7MShares$105 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$38.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$36.6 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$30.7 Million1.26% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.71MShares$27.9 Million0.27% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $447M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...